Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Completing the Drug Design Jigsaw

By University of East Anglia | October 5, 2017

A powerful new way of analysing how drugs interact with molecules in the body could aid the design of better treatments with fewer side-effects.

Most pharmaceuticals work by binding to a small site on the large proteins they target, causing the protein to change shape and so also its activity.

To find drugs that act specifically against a protein without also binding to others that are similar – and so causing side effects – it is important to understand this binding site in detail. Many current techniques can only provide partial information, giving details about which parts of the drug itself are important and, in some cases, the overall structure of the protein.

Researchers at the University of East Anglia have now developed a new approach that can reveal the other side of the jigsaw puzzle – which parts of the protein interact with the drug. It adapts a technique known as ligand-based Nuclear Magnetic Resonance (NMR) spectroscopy to reveal which amino acids in the protein are involved in binding to the drug.

They were able to do this by examining the drug and without having to label the protein, as is required in some other methods.

“Designing novel drugs is a bit like finding the proper piece that fits into a jigsaw puzzle,” said Dr Jesus Angulo, a senior lecturer at the University of East Anglia’s school of pharmacy who led the research. “It is not just the shape but also graphical content on the piece that must match the surrounding picture.

“Our novel approach allows us to now find the exact piece that matches the complementary shape and graphical content in a protein binding site.”

The new NMR technique, which is called DEEP-STD NMR, is described in the journal Angewandte Chemie.

It is based on an existing NMR technique used to study drug-protein interactions called STD-NMR. This works by exciting all of the amino acids in a protein by irradiating them.

It is then possible to look for where this excited state is transferred to chemical sites on the drug when it binds to it. This approach is similar to covering the protein with paint and then pressing the drug against it to see which parts get stained.

But Dr Angulo and his colleagues, whose work was funded by the BBSRC, found it is possible to irradiate the protein with different frequencies to excite different types of amino acid.

This allowed them to unpick which amino acids in the protein’s binding site are directly in contact with the drug from the “paint marks” they leave behind.

This means they only have to look at the drug to work out the important parts of the protein that are being targetted. They were able to get further information about the amino acids involved by using a combination of deuterium oxide, or heavy water, and normal water as a solvent.

The team, which included researchers at the Quadram Institute in Norwich, demonstrated their method on two well-studied proteins – an enzyme called intramolecular trans-sialidase, which is produced by a bacterium found in the human gut, and a subunit of the Cholera Toxin.

Dr Angulo said: “Our new method gives researchers a powerful tool to indirectly understand the architecture of the protein binding pocket.

“This will allow them to determine what are the best chemical requirements for a drug to interact specifically with a given protein receptor. This could to lead to stronger and more selective drug candidates, while lower amounts would be needed to trigger the desired effect.”


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50